FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285404793> ?p ?o ?g. }

• W4285404793 endingPage "e79" @default.
• W4285404793 startingPage "e73" @default.
• W4285404793 abstract "Purpose Stereotactic body radiation therapy (SBRT) has become a new therapeutic option for primary renal cell carcinoma. However, treatment doses lack consistency in the literature. The primary objective of this study was to determine the maximum tolerated dose for renal cancer SBRT. Methods and Materials This phase 1 multicentric dose-escalation study assessed 4 dose levels: 8 Gy × 4, 8 Gy × 5, 10 Gy × 4, and 12 Gy × 4. The primary objective of this study was to determine the maximal tolerated dose, defined by the occurrence of dose-limiting toxicity was defined as any acute side effect of grade ≥4 based on the Common Terminology Criteria for Averse Events, version 4.0. Results From October 2010 to September 2017, 13 patients were enrolled. The median follow-up was 23 months. There was no dose-limiting toxicity in our study, and the highest dose was reached successfully. No acute or late toxic effects above grade 2 were seen. There was no significant alteration of renal function after treatment. At 24 months, 2 patients had partial response and the others had stable disease. Conclusions After 24 months of follow-up, no dose-limiting toxicity was seen at any of the prescribed dose levels in our study. The findings suggest that our last dose level of 48 Gy in 4 12-Gy fractions can be considered safe and can be used in further studies." @default.
• W4285404793 created "2022-07-14" @default.
• W4285404793 creator A5012310739 @default.
• W4285404793 creator A5019998379 @default.
• W4285404793 creator A5037573673 @default.
• W4285404793 creator A5054669965 @default.
• W4285404793 creator A5060198821 @default.
• W4285404793 creator A5067708376 @default.
• W4285404793 creator A5086642518 @default.
• W4285404793 date "2023-01-01" @default.
• W4285404793 modified "2023-10-03" @default.
• W4285404793 title "Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Cancer: 24-Month Results of the RSR1 Phase 1 Dose Escalation Study" @default.
• W4285404793 cites W1822261498 @default.
• W4285404793 cites W1964276165 @default.
• W4285404793 cites W1977258176 @default.
• W4285404793 cites W1990078200 @default.
• W4285404793 cites W1992558528 @default.
• W4285404793 cites W1994435768 @default.
• W4285404793 cites W2015107633 @default.
• W4285404793 cites W2016177359 @default.
• W4285404793 cites W2018876835 @default.
• W4285404793 cites W2033295431 @default.
• W4285404793 cites W2039842156 @default.
• W4285404793 cites W2041595467 @default.
• W4285404793 cites W2047299114 @default.
• W4285404793 cites W2049887438 @default.
• W4285404793 cites W2054141638 @default.
• W4285404793 cites W2064275611 @default.
• W4285404793 cites W2074450945 @default.
• W4285404793 cites W2076676662 @default.
• W4285404793 cites W2087887230 @default.
• W4285404793 cites W2106602966 @default.
• W4285404793 cites W2113691296 @default.
• W4285404793 cites W2114920956 @default.
• W4285404793 cites W2121639352 @default.
• W4285404793 cites W2123524595 @default.
• W4285404793 cites W2130363617 @default.
• W4285404793 cites W2144803137 @default.
• W4285404793 cites W2150255388 @default.
• W4285404793 cites W2156943692 @default.
• W4285404793 cites W2162427240 @default.
• W4285404793 cites W2163565210 @default.
• W4285404793 cites W2345180720 @default.
• W4285404793 cites W2587017049 @default.
• W4285404793 cites W2590692105 @default.
• W4285404793 cites W2609997401 @default.
• W4285404793 cites W2612074997 @default.
• W4285404793 cites W2753913404 @default.
• W4285404793 cites W2761139472 @default.
• W4285404793 cites W2779215734 @default.
• W4285404793 cites W2781284646 @default.
• W4285404793 cites W2917524635 @default.
• W4285404793 cites W2927817491 @default.
• W4285404793 cites W2982108766 @default.
• W4285404793 cites W3023480357 @default.
• W4285404793 cites W4238108031 @default.
• W4285404793 cites W4322699831 @default.
• W4285404793 doi "https://doi.org/10.1016/j.prro.2022.06.012" @default.
• W4285404793 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35842186" @default.
• W4285404793 hasPublicationYear "2023" @default.
• W4285404793 type Work @default.
• W4285404793 citedByCount "2" @default.
• W4285404793 countsByYear W42854047932023 @default.
• W4285404793 crossrefType "journal-article" @default.
• W4285404793 hasAuthorship W4285404793A5012310739 @default.
• W4285404793 hasAuthorship W4285404793A5019998379 @default.
• W4285404793 hasAuthorship W4285404793A5037573673 @default.
• W4285404793 hasAuthorship W4285404793A5054669965 @default.
• W4285404793 hasAuthorship W4285404793A5060198821 @default.
• W4285404793 hasAuthorship W4285404793A5067708376 @default.
• W4285404793 hasAuthorship W4285404793A5086642518 @default.
• W4285404793 hasConcept C121608353 @default.
• W4285404793 hasConcept C126322002 @default.
• W4285404793 hasConcept C126894567 @default.
• W4285404793 hasConcept C127413603 @default.
• W4285404793 hasConcept C143998085 @default.
• W4285404793 hasConcept C188198153 @default.
• W4285404793 hasConcept C19831878 @default.
• W4285404793 hasConcept C2777472916 @default.
• W4285404793 hasConcept C2777793932 @default.
• W4285404793 hasConcept C2778120868 @default.
• W4285404793 hasConcept C2780035454 @default.
• W4285404793 hasConcept C2780387249 @default.
• W4285404793 hasConcept C29730261 @default.
• W4285404793 hasConcept C2989005 @default.
• W4285404793 hasConcept C509974204 @default.
• W4285404793 hasConcept C71924100 @default.
• W4285404793 hasConcept C78519656 @default.
• W4285404793 hasConcept C98274493 @default.
• W4285404793 hasConceptScore W4285404793C121608353 @default.
• W4285404793 hasConceptScore W4285404793C126322002 @default.
• W4285404793 hasConceptScore W4285404793C126894567 @default.
• W4285404793 hasConceptScore W4285404793C127413603 @default.
• W4285404793 hasConceptScore W4285404793C143998085 @default.
• W4285404793 hasConceptScore W4285404793C188198153 @default.
• W4285404793 hasConceptScore W4285404793C19831878 @default.
• W4285404793 hasConceptScore W4285404793C2777472916 @default.
• W4285404793 hasConceptScore W4285404793C2777793932 @default.

• next